Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSona Nanotech Inc

Sona Nanotech Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.28 CAD 0.00(0%)
Last update at 2026-11-10T20:23:00Z
Market Cap
35.46M

Momentum Score

…

Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. It also engages in the development of targeted hyperthermia therapy, a photo thermal therapy for the treatment of cancer tumors; and diagnostic tools comprising lateral flow assay rapid and bovine tuberculosis tests. The company was founded in 2013 and is based in Halifax, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.28
Low
0.28
High
52 Week Price Range
0.28
Low
0.84
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sona Nanotech Inc is a Canadian nanotechnology firm developing gold nanorod platforms for diagnostic and therapeutic uses. Long-term growth drivers include adoption in point-of-care diagnostics, expansion into imaging or therapeutic applications, and licensing or collaboration opportunities; the platform could address sensitivity and safety limitations of conventional nanoparticles. Principal risks are early-stage operations with limited revenues, financing and dilution exposure, regulatory and technical execution hurdles, and competition from established nanotechnology and medical device companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.28
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-392.94%
Net Debt
0.19M
ROCE
-1277.26%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -3.25M -2.70M -2.50M -2.36M -10.37M
Net income -3.25M -2.70M -2.50M -2.36M -10.37M
Selling general administrative 1.75M 1.91M 1.93M 3.21M 10.54M
Reconciled depreciation 0.72M 0.73M 0.46M 0.06M 0.07M
Ebit - - - -3.02M -10.67M
Ebitda - - - -2.22M -10.28M
Operating income -3.44M -2.92M -2.62M -2.73M -10.73M
Interest expense 0.04M 0.00M 0.01M 0.01M 0.02M
Interest income - 0.05M 0.07M 0.09M 0.02M
Net interest income -0.04M -0.05M -0.07M -0.08M -0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.44M 2.92M 2.65M 3.14M 10.73M
Total other income expense net 0.22M 0.27M 0.22M 0.86M 0.39M
Net income from continuing ops -3.25M -2.70M -2.50M -2.36M -10.37M
Net income applicable to common shares - -2.70M -2.50M -2.36M -10.37M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 1.33M 3.75M 2.75M 0.52M 1.52M
Intangible assets - 1.75M 2.47M - -
Total liab 1.37M 1.24M 1.59M 1.03M 2.75M
Total stockholder equity -0.04M 2.51M 1.16M -0.51M -1.22M
Other current liab - - - 0.09M 0.83M
Common stock - 21.99M 18.67M 14.32M 12.68M
Capital stock 22.36M 21.99M 18.67M 14.32M 12.68M
Retained earnings -24.05M -22.27M -20.25M -19.51M -25.99M
Cash 0.12M 1.85M 0.11M 0.16M 1.18M
Total current liabilities 1.06M 0.84M 1.06M 0.42M 2.05M
Net debt 0.19M - 0.42M 0.45M 0.15M
Short term debt - 0.00M 0.00M 0.00M 0.00M
Short long term debt - - - - 0.64M
Other stockholder equity - - - 0.57M 0.57M
Property plant equipment - 0.00M 0.01M 0.05M 0.11M
Total current assets 0.30M 2.00M 0.26M 0.47M 1.41M
Net tangible assets - - - -0.51M -1.22M
Short term investments 0.00M 0.00M 0.01M 0.01M 0.01M
Net receivables 0.11M 0.10M 0.05M 0.25M 0.13M
Long term debt 0.31M 0.39M 0.53M 0.61M 0.70M
Accounts payable 0.91M 0.65M 0.90M 0.33M 0.58M
Non current assets total 1.03M 1.75M 2.48M 0.05M 0.11M
Long term debt total - 0.39M 0.53M 0.61M 0.70M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments - 0.00M 0.01M 0.00M -
Change to liabilities - - - -0.03M -1.26M
Total cashflows from investing activities - 0.00M 0.01M - 0.00M
Net borrowings - - - 0.00M 0.10M
Total cash from financing activities 0.23M 3.70M 1.20M 0.78M 4.89M
Net income -3.25M -2.70M -2.50M -2.36M -10.37M
Change in cash -1.73M 1.75M -0.05M -1.03M 1.08M
Begin period cash flow 1.85M 0.11M 0.16M 1.18M 0.10M
End period cash flow 0.12M 1.85M 0.11M 0.16M 1.18M
Total cash from operating activities -1.96M -1.96M -1.26M -1.81M -3.81M
Issuance of capital stock 0.00M 3.70M 1.01M 0.55M 2.25M
Depreciation 0.72M 0.01M 0.04M 0.06M 0.07M
Other cashflows from investing activities - 0.00M 0.01M - -
Change to account receivables - - - -0.08M -0.14M
Sale purchase of stock - 3.70M 1.01M 0.59M 4.34M
Other cashflows from financing activities - 0.00M 0.19M 0.18M 0.74M
Change to netincome - - - 0.60M 7.88M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.18M -0.20M 0.76M -0.11M -1.40M
Stock based compensation 0.48M 0.35M 0.29M 1.47M 8.24M
Other non cash items -0.09M -0.14M -0.27M -0.46M -0.35M
Free cash flow -1.96M -1.96M -1.26M -1.81M -3.81M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SONA
Sona Nanotech Inc		 -
-%		 0.28 - - 495.02 110.83 434.31 54.97
BUX
BioMark Diagnostics Inc		 -0.03
6.67%		 0.42 - - 664.18 119.98 657.92 -27.36
IZO
Izotropic Corporation		 -
-%		 0.12 - 2.27 - 114.27 - -5.29

Profile*

Sona Nanotech Inc

Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. It also engages in the development of targeted hyperthermia therapy, a photo thermal therapy for the treatment of cancer tumors; and diagnostic tools comprising lateral flow assay rapid and bovine tuberculosis tests. The company was founded in 2013 and is based in Halifax, Canada.

Purdy?s Wharf Tower II, Halifax, NS, Canada, B3J 3R7

902-442-0653

https://www.sonanano.com

Name Title Year Born
Mr. David Andrew Regan Chief Executive Officer 1969
Mr. Robert William George Randall CPA CFO & Corporate Secretary 1963
Dr. Len Pagliaro Ph.D. CSO & Director NA
Dr. Carman Giacomantonio M.D., M.Sc. Chief Medical Officer NA
Dr. Kulbir Singh Ph.D. Co-Founder & Head of R&D NA
Dr. Mike McAlduff Director of R&D & Production and Founder NA
Dr. Gerrard Marangoni Co-Founder & Member of Scientific Advisory Board NA
Mr. Darren Rowles Head of Diagnostics 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…